BiotechTube

Ravulizumab

Pre-clinicalActive
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Paroxysmal Nocturnal Haemoglobinuria

Conditions

Paroxysmal Nocturnal Haemoglobinuria

Trial Timeline

Feb 6, 2025 → Aug 1, 2028

NCT ID
NCT06633536

About Ravulizumab

Ravulizumab is a pre-clinical stage product being developed by AstraZeneca for Paroxysmal Nocturnal Haemoglobinuria. The current trial status is active. This product is registered under clinical trial identifier NCT06633536. Target conditions include Paroxysmal Nocturnal Haemoglobinuria.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (3)

NCT IDPhaseStatus
NCT07399730Pre-clinicalRecruiting
NCT06909253Pre-clinicalRecruiting
NCT06633536Pre-clinicalActive

Competing Products

20 competing products in Paroxysmal Nocturnal Haemoglobinuria

See all competitors
ProductCompanyStageHype Score
Crovalimab + EculizumabChugai PharmaceuticalPhase 3
77
Crovalimab + PlaceboChugai PharmaceuticalPhase 1/2
41
Crovalimab + EculizumabChugai PharmaceuticalPhase 3
77
EculizumabAstraZenecaPhase 3
77
DanicopanAstraZenecaPhase 3
77
LNP023NovartisPre-clinical
23
Iptacopan (LNP023)NovartisPhase 3
77
iptacopanNovartisPhase 2
52
LNP023NovartisPhase 2
52
IptacopanNovartisPre-clinical
23
IptacopanNovartisPhase 3
77
LNP023 + Eculizumab + RavulizumabNovartisPhase 3
77
LNP023NovartisPhase 3
77
LFG316 + LNP023NovartisPhase 2
52
IptacopanNovartisPhase 3
77
CrovalimabRochePhase 3
77
ABP 959 + EculizumabAmgenPhase 3
76
PegcetacoplanSwedish Orphan BiovitrumPre-clinical
22
BMS-919373 + Placebo (Matching with BMS-919373)Bristol Myers SquibbPhase 2
51
Humanized anti-Factor Bb monoclonal antibody + PlaceboSanofiPhase 1
32

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85